Skip to content
2000
Volume 31, Issue 2
  • ISSN: 0929-8665
  • E-ISSN: 1875-5305

Abstract

Phage therapy, a promising alternative to combat multidrug-resistant bacterial infections, harnesses the lytic cycle of bacteriophages to target and eliminate bacteria. Key players in this process are the phage lysis proteins, including holin, endolysin, and spanin, which work synergistically to disrupt the bacterial cell wall and induce lysis. Understanding the structure and function of these proteins is crucial for the development of effective therapies. Recombinant versions of these proteins have been engineered to enhance their stability and efficacy. Recent progress in the field has led to the approval of bacteriophage-based therapeutics as drugs, paving the way for their clinical use. These proteins can be combined in phage cocktails or combined with antibiotics to enhance their activity against bacterial biofilms, a common cause of treatment failure. Animal studies and clinical trials are being conducted to evaluate the safety and efficacy of phage therapy in humans. Overall, phage therapy holds great potential as a valuable tool in the fight against multidrug- resistant bacteria, offering hope for the future of infectious disease treatment.

Loading

Article metrics loading...

/content/journals/ppl/10.2174/0109298665181166231212051621
2024-02-01
2025-07-04
Loading full text...

Full text loading...

/content/journals/ppl/10.2174/0109298665181166231212051621
Loading

  • Article Type:
    Review Article
Keyword(s): bacteriophage; holin; Multidrug-resistant; multigene lysis; phage endolysin; spanin
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test